Seroconversion to Multiple Islet Autoantibodies and Risk of Progression to Diabetes in Children

Key Points

• Determine the long-term risk of developing clinical type 1 diabetes in at-risk children following seroconversion to multiple islet autoantibodies.
• Tracked children at risk for type 1 diabetes longitudinally over a 15-year follow-up period.
• Evaluated the development of multiple islet autoantibody seroconversion and monitored subsequent progression to clinical diabetes.
• The majority of at-risk children with multiple islet autoantibody seroconversion progressed to clinical type 1 diabetes over 15 years.
• Identified children positive for multiple autoantibodies as the primary high-risk target group for future preventive intervention trials.